Every $1 invested in the Medicines for Malaria Venture (MMV) between 2000 and 2023 yielded $13 in monetised health benefits, according to a study published in The Lancet Global Health this week. MMV is a not-for-profit product development partnership (PDP) that works with public and private sector partners to discover, develop and deliver accessible and […] Continue reading ->
The $9.4 billion package agreed to by the US Senate and House Appropriations Committees, is more than double the $3.7 billion requested by the Trump Administration, and signals bipartisan support for maintaining significant global health aid – although the package still must be approved by both Senate and House, and could also be vetoed by […] Continue reading ->
In Kenya, toxicologists and epidemiologists face a difficult choice: to pursue better-paid work to support their families, or volunteer as reviewers for vaccine clinical trials, often without the compensation needed to cover even their children’s school fees. Their dilemma underscores a broader challenge in Africa’s clinical research ecosystem. Slow, duplicative approval processes and limited regulatory […] Continue reading ->
Global malaria programmes have helped to save an estimated 14 million lives between 2000 and 2024, but growing drug resistance is threatening to undermine years of hard-won gains, a new World Health Organization (WHO) report has shown. Last year, the world recorded 282 million malaria cases and more than 600,000 deaths, with Africa accounting for […] Continue reading ->
Artificial intelligence could compress years of drug discovery into months – helping to overcome growing drug resistance to existing treatments for malaria and other vector-borne diseases. But scientists in low-income countries are often left behind. Jeremy Burrows, Medicines for Malaria Venture (MMV) vice president, head of drug discovery, explains how a new open-access, AI-powered drug discovery […] Continue reading ->